EXECUTIVE SUMMARY

First nine months of 2026

Main figures €Mn

Op. Revenue	EBITDA	EBIT
610.2 (+16%)	226.6 (+52%)	198.7 (+56%)
Net profit	**Capex**	**Net debt**
162.8 (+67%)	50.3 (+31%)	(27.9)


Updated 2026 Outlook

Operating revenue expected to grow mid-to-high single-digit vs. 2025, from the previously expected low-to-mid single-digit growth

2027 guidance to be provided with FY 2026 results, expected in February 2027


- ✓ Phoenix acquisition completed on April 1, 2026. Preliminary purchase price allocation resulted in a €62.4 Mn bargain purchase gain (badwill), recognized as non-recurring income in the consolidated income statement.

Operating revenue €Mn



Specialty pharma business €Mn

Total
€346.1m
+1%



€297.6m -1% Prescription products

€47.8m +10% Contrast agents

€0.8m +18% Other

Heparin franchise*
30% of operating revenue
€180.9m -5%

Enoxaparin sales €107.0m -5%

Bemiparin sales €66.7m -6%

- ✓ This performance was caused by a contraction in international sales, mainly due to overstocking by international partners.
- ✓ Despite YoY decline, ROVI expects bemiparin sales to be stronger in Q4, driven by the year-end concentration of international orders.

LMWH 2026 guidance improved

- ✓ Sales expected to decline by a mid single-digit percentage vs. 2025 (vs. a high-single-digit decline previously expected) due to lower orders from partners and pricing pressure

Other prescription-based pharmaceutical products

Neparvis® €43.3m +3%

Okedi® €53.0m +29%

- ✓ Risperidone ISM®, a LAI of risperidone for schizophrenia.
- ✓ Marketed in Europe, Australia & Taiwan.

*** LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins**


CDMO(1) business €Mn

Total
€263.9m




(*) "Other operating revenue" includes service activities that are not material to the Group. In 9M 2025 results release, this amount was included within the "Contrast agents and other hospital products" line.
(1) Contract Development and Manufacturing Organisation
To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 32-36) of the press release on the financial results for the first nine months of 2026. Said document is available on ROVI's website and may be accessed on the following link https://www.rovi.es/en/shareholders-investors/financial-business-information


Gross profit €Mn



SG&A expenses €Mn



EBITDA €Mn



R&D expenses €Mn €58.4 +136%


Product	Potential Indication	Current Situation	Key Milestones
Risperidone ISM®, monthly	**Schizophrenia**	Approved	Marketed in Europe, in Australia & Taiwan
Letrozole ISM®, annual	**Breast Cancer**	Clinical development on hold	Phase I: Superior oestrogen suppression vs Femara®
Letrozole SIE[1], quarterly	**Breast Cancer**	Completion of phase I	Phase I: positive readout confirms superior estrogen suppression vs Femara®. Phase III started in Q3 2026
Risperidone ISM®, quarterly	**Schizophrenia**	Completion of phase I	Phase I: positive readout allows progression to phase III clinical trial

Concentrated on improving posology for already approved compounds, which benefits risk / reward profile

Multiple FDA / GMP approved facilities to support the platform

EBITDA Pre-R&D and pre-badwill[2] €Mn €222.7m +28%

Net profit €Mn



Closing remarks

- ✓ Strong momentum in CDMO business: consistent and focused execution
- ✓ Value creation from the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA)
- ✓ Vertical integration of the heparin division to enhance cost efficiency and improve competitiveness
- ✓ Sustained growth of the specialty pharmaceutical business, driven by Okedi®
- ✓ Strong R&D investment, with two Phase III clinical trials: Letrozole SIE initiated in Q3 2026 and Risperidone QUAR expected in Q4 2026

(1) Superior Inhibition of Estrogens; (2) calculated excluding badwill in 9M 2026 and R&D expenses in 9M 2025 and in 9M 2026.
To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 32-36) of the press release on the financial results for the first nine months of 2026. Said document is available on ROVI's website and may be accessed on the following link https://www.rovi.es/en/shareholders-investors/financial-business-information